There are multiple options that impact glycemic control.

GLP-1 RAs work in 3 ways
to impact multiple pathophysiological defects of type 2 diabetes1

[Illustration 1 of 3 - organs w/captions]

Stimulate glucose-dependent insulin release

[Illustration 2 of 3 - organs w/captions]

Reduce hepatic glucose production by decreasing glucagon secretion

[Illustration 3 of 3 - organs w/captions]

Slow gastric emptying

Mechanism of Action

See how Trulicity was designed with patients in mind.

When a patient’s A1C is 7.3%-10.2%, the relative contribution of fasting and postprandial hyperglycemia to overall hyperglycemia is ~40%-60%2

Study Description

  • 290 noninsulin, nonacarbose treated patients with type 2 diabetes were enrolled in this study
  • Plasma glucose (PG) data was collected at 8 am, 11 am, 2 pm, and 5 pm
  • Area under the curve above fasting PG (AUC1) was used as a measure of postprandial glucose increments and AUC2-AUC1 as a measure of fasting glucose increments where AUC2 is area under the curve above 6.1 mmol/L
  • Relative contribution of postprandial and fasting plasma glucose increments to overall diurnal hyperglycemia was assessed for each quintile of baseline A1C

Reductions in both fasting and postprandial serum glucose (FSG and PPG) were observed 48 hours after a single dose of once-weekly Trulicity3-6

Study Description

  • 6-week, multicenter, parallel-design, double-blind, part-randomized, placebo-controlled, multiple-dose, phase 1 study in patients ≥65 years old with type 2 diabetes treated with oral antihyperglycemic medications except sulfonylureas, disaccharidase inhibitors, and meglitinides
  • Study arms included placebo (n=8); Trulicity 0.5 mg (n=9), not a marketed dose; Trulicity 0.75 (n=11); and Trulicity 1.5 mg (n=9)
  • Primary objective was to evaluate the safety and tolerability of Trulicity 0.5 mg, 0.75 mg, and 1.5 mg for 6 weeks; mixed effect linear model; primary objective met
  • Data presented are LS mean change from baseline and are secondary endpoints

These data are from a pharmacodynamics study.

The 2018 ADA/EASD consensus report recommends considering a GLP-1 RA in most patients with type 2 diabetes prior to insulin*1

*After oral medication in patients with no symptoms of hyperglycemia.

Consider insulin as first injectable if

  • A1C >11%
  • Symptoms or evidence of catabolism: weight loss, polyuria, or polydipsia, which suggest insulin deficiency
  • Type 1 diabetes is a possibility

See the abridged American Diabetes Association therapy recommendations for patients with type 2 diabetes here.

Indication and Important Safety Information 
WARNING: POTENTIAL RISK OF THYROID TUMORS INCLUDING THYROID CANCER

Indication and Important Safety Information 
WARNING: POTENTIAL RISK OF THYROID TUMORS INCLUDING THYROID CANCER

Back to top